Several big biotech and pharma companies have been buzzing about their plans to launch biosimilar programs now that the FDA is laying out a regulatory pathway for the therapies. Reuters pinned down several CEOs at the JP Morgan event, and Amgen’s Kevin Sharer as well as Biogen Idec’s George Scangos talked up plans to fire [...]
The aggregated proteins strewn about the brain are the hallmark of one of the most common neurodegenerative disorders: Alzheimer’s disease. But while these irregular, gunky proteins, called amyloid-β, are believed to contribute to the deterioration of memory and cognitive ability in Alzheimer’s patients, no one knows how they lead to these symptoms, and the severity [...]
Underscoring the rapid global shift of drug R&D into China, Eli Lilly announced plans to set up a new research center in Shanghai that will initially hire up about 100 scientists and support staff to explore new therapies for diabetes and its twin co-morbidities–obesity and cardiovascular disease.
The side effects of the standard medication for Parkinson’s disease have long been a preoccupation of brain researchers. Now Daniella Rylander has presented new findings in a recently defended PhD thesis at Lund University that provide hope of more effective medication for those who suffer from the nerve cell disease.
Sanofi-Aventis is going to Harvard this fall for some post-grad work in drug development. The Big Pharma company–which has been trumpeting its intention to partner up with academics and biotech companies rather than rely entirely on its own in-house research–and the Ivy League institution announced a research pact this morning, with a special focus on [...]
Third Rock Ventures and Prospect Venture Partners have partnered on a $33 million Series A for NinePoint Medical, a Cambridge, MA-based startup that is developing new technology that can be used to examine gastrointestinal tissue for precancerous and cancerous cells.
When the economic crisis reached its peak in 2009, biotech companies were hit hard. We buried 16 developers in our first annual Biotech Graveyard list last year, and while that number has dropped significantly in 2010, there were still eight biotechs that simply couldn’t find a buyer or the money necessary to continue their run. [...]
The Indian pharmaceutical industry has been shaken up lately, worried that multinational drugmakers will come in and completely take over their drug market. The fears aren’t unfounded; Big Pharma, after all, has been targeting the subcontinent as a key location for expansion, as sales-growth slows in the U.S. and Europe.
Yes, Star Trek geeks can rejoice. There is now a “cloaking device” for drug delivery. At least, that’s how researchers at the University of Massachusetts Amherst describe what they’re doing. In the current issue of Nature Chemistry, Vincent Rotello says he and his team can deliver a dormant toxin into a specific site such [...]
Singapore strengthened its research and development focus on money-making outcomes and will set up a S$1.35 billion ($1 billion) fund to promote closer ties with the science and technology industries. Out of the $16.1 billion the government has budgeted to spend on research and development from 2011 to 2015, 70 percent will be for projects [...]
You are currently browsing the weblog archives for 'Strategic Alliances in World Pharma and Biotech Markets' tag.
Longer entries are truncated. Click the headline of an entry to read it in its entirety.
Biotech Trading Signals Pharma News Biotech News